|Other names||Metaproterenol (USAN US)|
|Inhalation (MDI) and tablets|
|Bioavailability||3% if inhaled, 40% if taken orally|
|Metabolism||Gastrointestinal and hepatic|
|Elimination half-life||6 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||211.261 g·mol−1|
|3D model (JSmol)|
|Solubility in water||9.7 mg/mL (20 °C)|
|(what is this?)|
Orciprenaline, also known as metaproterenol, is a bronchodilator used in the treatment of asthma. Orciprenaline is a moderately selective β2 adrenergic receptor agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on α adrenergic receptors. The pharmacologic effects of β adrenergic agonist drugs, such as orciprenaline, are at least in part attributable to stimulation through β adrenergic receptors of intracellular adenylyl cyclase, the enzyme which catalyzes the conversion of ATP to cAMP. Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from many cells, especially from mast cells.
Possible side effects
- Rare side effects that could be life-threatening
- increased difficulty breathing
- rapid or increased heart rate
- irregular heartbeat
- chest pain or discomfort
- Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). "DrugBank 3.0: a comprehensive resource for omics research on drugs". Nucleic Acids Res. 39 (Database issue): D1035-41. doi:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). "DrugBank: a knowledgebase for drugs, drug actions and drug targets". Nucleic Acids Res. 36 (Database issue): D901-6. doi:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.